<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04010383</url>
  </required_header>
  <id_info>
    <org_study_id>2018-01902</org_study_id>
    <nct_id>NCT04010383</nct_id>
  </id_info>
  <brief_title>Non-inferiority Study for Visual Field Measurements Using a Virtual Reality Device</brief_title>
  <official_title>Non-inferiority Study for Visual Field Measurements Using a Virtual Reality Device on Participants With Normal and Glaucomatous Visual Fields</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that performing VF measurements with a Virtual Reality headset using&#xD;
      similar testing strategies as implemented in conventional perimeters, allow for a&#xD;
      non-inferior quality in VF acquisitions. The results of this study will show if valid&#xD;
      measurements of such devices in human subjects can be obtained.&#xD;
&#xD;
      The primary endpoint of this study is the non-inferiority estimation quality of participant's&#xD;
      mean defect (MD) measured in decibel (dB) between the head-mounted display and an OCTOPUS&#xD;
      perimeter using the dynamic strategy (DS) for participants with normal or glaucomatous visual&#xD;
      field. The MD is a clinical measure for the average loss of visual function calculated from&#xD;
      the visual field of a participant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>non-inferiority estimation quality of mean defect (MD) measured in decibels (dB) between the virtual reality perimeter and the OCTOPUS 900 perimeter</measure>
    <time_frame>2 weeks</time_frame>
    <description>The primary endpoint of this study is the non-inferiority estimation quality of participant's mean defect (MD) measured in decibel (dB) between the head-mounted display and an OCTOPUS perimeter using the dynamic strategy (DS) for participants with normal or glaucomatous visual field. The MD is a clinical measure for the average loss of visual function calculated from the visual field of a participant.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">70</enrollment>
  <condition>Visual Field Tests</condition>
  <arm_group>
    <arm_group_label>normal visual field subjects</arm_group_label>
    <description>Cataract yes or no&#xD;
Age range 40 - 80 years&#xD;
normal visual field (MD: &lt; +2 dB)&#xD;
Refractive error within ±5 dpt. spherical equivalent&#xD;
Astigmatism of &lt; -3 dpt.&#xD;
Visual acuity of ≥0.3 logMar (decimal ≥0.5)&#xD;
Experience in perimetry (history of at least one perimetry examination)&#xD;
False positive or negative errors each less than 20% in each examination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucomatous subjects</arm_group_label>
    <description>Primary open-angle/ pseudoexfoliation/ primary angle-closure glaucoma&#xD;
Early to moderate visual field loss (MD: +2 to +12 dB)&#xD;
Refractive error within ±5 dpt. spherical equivalent&#xD;
Astigmatism of &lt; -3 dpt.&#xD;
Visual acuity of ≥0.3 logMar (decimal ≥0.5)&#xD;
Experience in perimetry (history of at least one perimetry examination)&#xD;
False positive or negative errors each less than 20% in each examination&#xD;
Cataract yes or no&#xD;
Age range 40 - 80 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>virtual reality perimeter</intervention_name>
    <description>Both groups will be examined with a standard automated perimeter as well as with the virtual reality perimeter.</description>
    <arm_group_label>Glaucomatous subjects</arm_group_label>
    <arm_group_label>normal visual field subjects</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of glaucoma patients and patients with normal visual fields&#xD;
        respecting the inclusion/exclusion criteria. There is no restriction in ethnicity.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Written informed consent&#xD;
&#xD;
        Inclusion Criteria for normal visual field subjects:&#xD;
&#xD;
          -  Cataract yes or no&#xD;
&#xD;
          -  Age range 40 - 80 years- normal visual field (MD: &lt; +2 dB)&#xD;
&#xD;
          -  Refractive error within ±5 dpt. spherical equivalent&#xD;
&#xD;
          -  Astigmatism of &lt; -3 dpt.&#xD;
&#xD;
          -  Visual acuity of ≥0.3 logMar (decimal ≥0.5)&#xD;
&#xD;
          -  Experience in perimetry (history of at least one perimetry examination)&#xD;
&#xD;
          -  False positive or negative errors each less than 20% in each examination&#xD;
&#xD;
        Inclusion Criteria for glaucomatous subjects:&#xD;
&#xD;
          -  Primary open-angle/ pseudoexfoliation/ primary angle-closure glaucoma&#xD;
&#xD;
          -  Early to moderate visual field loss (MD: +2 to +12 dB)&#xD;
&#xD;
          -  Refractive error within ±5 dpt. spherical equivalent&#xD;
&#xD;
          -  Astigmatism of &lt; -3 dpt.&#xD;
&#xD;
          -  Visual acuity of ≥0.3 logMar (decimal ≥0.5)&#xD;
&#xD;
          -  Experience in perimetry (history of at least one perimetry examination)&#xD;
&#xD;
          -  False positive or negative errors each less than 20% in each examination&#xD;
&#xD;
          -  Cataract yes or no&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria are subjects younger than 40 and older than 80 years&#xD;
&#xD;
          -  Inability to follow the procedure&#xD;
&#xD;
          -  Insufficient knowledge of project language&#xD;
&#xD;
          -  The history of other ocular diseases than glaucoma or cataract or other conditions&#xD;
             that might affect visual field testing (e.g. pituitary lesions, demyelinating&#xD;
             diseases).&#xD;
&#xD;
          -  Any history of epilepsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>René G Höhn, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, University Hospital Bern, Berne, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Bern, Department of Ophthalmology</name>
      <address>
        <city>Berne</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Perimetry</keyword>
  <keyword>Virtual reality device</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

